v3.26.3
RELATED PARTY TRANSACTIONS
9 Months Ended
Sep. 30, 2026
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS
NOTE 10: RELATED PARTY TRANSACTIONS

 

In connection with the acquisition of Oratech completed on March 25, 2026, the Company entered into various financing and commercial arrangements with Oramed, which is considered a related party to the Company due to its significant ownership interest in the Company and representation on the Company’s board of directors.

 

  a. Related Party Financing Arrangements

 

As part of the transaction, the Company issued convertible promissory notes and warrants to Oramed. As of September 30, 2026, the Company recorded convertible promissory notes, net, of approximately $4.4 million attributable to Oramed. As of September 30, 2026, the warrants issued to Oramed were classified as equity and, accordingly, are no longer reflected as liabilities.

 

Refer to Note 3, Significant Accounting Policies, and Note 9, Convertible Notes, for additional information regarding the terms and accounting treatment of these financing arrangements.

 

  b. Asset Acquisition Transaction

 

In connection with the transaction, the Company completed the acquisition of Oratech pursuant to a SPA entered into with Oramed. Refer to Note 6, Asset Acquisition, for additional information regarding the transaction and the related accounting treatment. The acquired assets primarily included intellectual property and other contractual rights related to Oratech’s product development and clinical trial activities. In connection with the transaction, the Company also entered into arrangements related to future clinical trial activities.

 

As part of the consideration transferred in the transaction, the Company issued pre-funded warrants and freestanding warrants to Oramed. As of September 30, 2026, such pre-funded warrants and freestanding warrants were classified as equity and, accordingly, are no longer reflected as liabilities.

 

In addition, the Company agreed to make revenue sharing payments to Oramed based on future sales, subject to certain caps and termination provisions. During the three and nine months ended September 30, 2026, the Company recognized revenue sharing expense of $66 thousand and $168 thousand, respectively.

 

During the nine months ended September 30, 2026, the Company recognized approximately $4.9 million, of research and development expense associated with acquired IPR&D assets that were determined to have no alternative future use.

 

  c. Clinical Trial Services Arrangements

 

The clinical trial services arrangements include future clinical development, project management, regulatory and operational support services expected to be provided over a 24-month period. Management’s estimate of the fair value associated with such arrangements required significant judgment and was based on assumptions regarding the scope of services, expected costs, specialized expertise, execution capabilities and market participant considerations. The Company believes the assumptions utilized are consistent with market participant assumptions.

 

During the three and nine months ended September 30, 2026, Oramed provided clinical trial management services totaling approximately $492 thousand and $1,114 thousand under these arrangements, which were recognized as research and development expense. The Company also recognized approximately $74 thousand and $167 thousand for the three and the nine months ended September 30, 2026, respectively, of research and development expense through the utilization of the clinical trial services asset recognized in connection with the Oratech acquisition. As of September 30, 2026, the clinical trial services asset amounted to $808 thousand, representing the estimated value of future clinical trial services expected to be provided under these arrangements.

 

Certain members of the Company’s Board of Directors are affiliated with Oramed, which is a significant shareholder and counterparty to the financing and commercial arrangements described above.

 

  d.

Related Party Legal expense

 

During the three and nine months ended September 30, 2026, the Company recognized $67 thousand of legal expense reimbursable to Oramed Pharmaceuticals Inc., a related party.